Vyome (NASDAQ:HIND) Upgraded to “Strong-Buy” at Chardan Capital

Vyome (NASDAQ:HIND) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research note issued on Thursday, Zacks reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Zacks Research raised shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.25.

Vyome Stock Up 2.3%

Vyome stock opened at $2.23 on Thursday. The stock has a 50-day simple moving average of $2.18 and a 200 day simple moving average of $2.28. Vyome has a 12-month low of $1.75 and a 12-month high of $9.56. The stock has a market capitalization of $15.65 million, a price-to-earnings ratio of -0.66 and a beta of 1.50.

Vyome (NASDAQ:HIND) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.The company had revenue of $0.27 million for the quarter. As a group, sell-side analysts anticipate that Vyome will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC purchased a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.06% of the company’s stock.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.